+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market 2019-2023 - Product Image

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market 2019-2023

  • ID: 4804046
  • Report
  • Region: Global
  • 127 Pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Eli LillyCo.
  • GlaxoSmithKline Plc
  • H. Lundbeck AS
  • Pfizer Inc.
  • MORE

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market: About this market

Selective Serotonin Reuptake Inhibitors (SSRIs) are used to treat severe or persistent depression by elevating the extracellular levels of serotonin. The selective serotonin reuptake inhibitors market analysis considers sales of the drugs for depression, anxiety and panic disorder, and other mental conditions. This analysis also considers the sales of selective serotonin reuptake inhibitors in Asia, Europe, North America, and ROW. In 2018, the depression segment held the highest market share, which is expected to remain prevalent over the forecast period. Factors such as the rising incidence of depression, easy absorption of the drugs through the gastrointestinal tracts, and their selective activity toward 5-HT receptors will significantly help the depression segment in maintaining its leading market position. Also, our global selective serotonin reuptake inhibitors report has observed market growth factors such as the increased drug dependency associated with SSRIs, rising prevalence of mental illnesses, and favorable drug purchasing policies for patients. However, challenges such as side effects of antidepressants, advent of biologics, and stringent US FDA regulations and approval of psychotropic drugs may hamper the growth of the selective serotonin reuptake inhibitors industry over the forecast period.

Global Selective Serotonin Reuptake Inhibitors (SSRIs) Market: Overview

Rising prevalence of mental illnesses

The rising prevalence of mental illnesses, especially in the US, has been increasing the sales of neurological drugs such as SSRIs. These drugs have proven efficacy in treating depression. SSRIs are more effective compared with other available antidepressants. The growth potential of the market will attract new entrants. Therefore, the market is expected to record a CAGR of almost 4% during the forecast period.

Growing geriatric population

Mental disorders are common among older adults. The primary reason being most of the geriatric population have two or more chronic health conditions such as cardiovascular disease, hypertension, diabetes, and cancer, which are high-risk factors for mental disorders. The prevalence rate of mental conditions among the geriatric population is rising. Favorable health insurance policies are allowing people of this age group to avail treatment for mental disorders. This is creating market opportunities for vendors. Therefore, the growing geriatric population will have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global selective serotonin reuptake inhibitors market is fragmented. This robust vendor analysis is designed to help clients in improving their market position, and in line with this, this report provides a detailed analysis of several leading selective serotonin reuptake inhibitors producers, which include Allergan Plc, Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, and Pfizer Inc.

Also, the selective serotonin reuptake inhibitors market analysis report includes information on upcoming trends and challenges that will influence the market growth. This is to help companies in strategizing and leveraging on all forthcoming growth opportunities.

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Eli LillyCo.
  • GlaxoSmithKline Plc
  • H. Lundbeck AS
  • Pfizer Inc.
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
  • Preface
  • Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY APPLICATION
  • Market segmentation by application
  • Comparison by application
  • Depression - Market size and forecast 2018-2023
  • Anxiety and panic disorder - Market size and forecast 2018-2023
  • Other mental conditions - Market size and forecast 2018-2023
  • Market opportunity by application
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS

PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Market positioning of vendors
  • Vendors covered
  • Vendor classification
  • Allergan Plc
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • H. Lundbeck AS
  • Pfizer Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Application - Market share 2018-2023 (%)
Exhibit 18: Comparison by application
Exhibit 19: Depression - Market size and forecast 2018-2023 ($ millions)
Exhibit 20: Depression - Year-over-year growth 2019-2023 (%)
Exhibit 21: Anxiety and panic disorder - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Prevalence of any anxiety disorder among US adults (2001-2003)
Exhibit 23: Past year severity of any anxiety disorder among US adults (2001-2003)
Exhibit 24: Anxiety and panic disorder - Year-over-year growth 2019-2023 (%)
Exhibit 25: Other mental conditions - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Prevalence of OCD among US adults (2001-2003)
Exhibit 27: Past year severity of OCD among US adults (2001-2003)
Exhibit 28: Other mental conditions - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by application
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in North America
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Prevalence scenario of AMI in US in 2017
Exhibit 48: Prevalence scenario of SMI in US in 2017
Exhibit 49: SSRI exposure 91 days either side of LMP and prevalence of congenital abnormality (CA) in three countries
Exhibit 50: Impact of drivers and challenges
Exhibit 51: Geriatric population scenario in US in 2017
Exhibit 52: CDC statistics about mental disorder in geriatric population in US over past few decades
Exhibit 53: Vendor landscape
Exhibit 54: Landscape disruption
Exhibit 55: Market positioning of vendors
Exhibit 56: Vendors covered
Exhibit 57: Vendor classification
Exhibit 58: Allergan Plc - Vendor overview
Exhibit 59: Allergan Plc - Business segments
Exhibit 60: Allergan Plc - Organizational developments
Exhibit 61: Allergan Plc - Geographic focus
Exhibit 62: Allergan Plc - Segment focus
Exhibit 63: Allergan Plc - Key offerings
Exhibit 64: Allergan Plc - Key customers
Exhibit 65: Eli Lilly and Co. - Vendor overview
Exhibit 66: Eli Lilly and Co. - Business segments
Exhibit 67: Eli Lilly and Co. - Organizational developments
Exhibit 68: Eli Lilly and Co. - Geographic focus
Exhibit 69: Eli Lilly and Co. - Segment focus
Exhibit 70: Eli Lilly and Co. - Key offerings
Exhibit 71: Eli Lilly and Co. - Key customers
Exhibit 72: GlaxoSmithKline Plc - Vendor overview
Exhibit 73: GlaxoSmithKline Plc - Business segments
Exhibit 74: GlaxoSmithKline Plc - Organizational developments
Exhibit 75: GlaxoSmithKline Plc - Geographic focus
Exhibit 76: GlaxoSmithKline Plc - Segment focus
Exhibit 77: GlaxoSmithKline Plc - Key offerings
Exhibit 78: GlaxoSmithKline Plc - Key customers
Exhibit 79: H. Lundbeck AS - Vendor overview
Exhibit 80: H. Lundbeck AS - Business segments
Exhibit 81: H. Lundbeck AS - Organizational developments
Exhibit 82: H. Lundbeck AS - Geographic focus
Exhibit 83: H. Lundbeck AS - Key offerings
Exhibit 84: H. Lundbeck AS - Key customers
Exhibit 85: Pfizer Inc. - Vendor overview
Exhibit 86: Pfizer Inc. - Business segments
Exhibit 87: Pfizer Inc. - Organizational developments
Exhibit 88: Pfizer Inc. - Geographic focus
Exhibit 89: Pfizer Inc. - Segment focus
Exhibit 90: Pfizer Inc. - Key offerings
Exhibit 91: Pfizer Inc. - Key customers
Exhibit 92: Validation techniques employed for market sizing
Exhibit 93: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • Allergan Plc
  • Eli LillyCo.
  • GlaxoSmithKline Plc
  • H. Lundbeck AS
  • Pfizer Inc.
  • MORE
The following companies are recognised as the key players in the global Selective Serotonin Reuptake Inhibitors (SSRIs) market: Allergan Plc, Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck AS, and Pfizer Inc.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the growing geriatric population.”

According to the report, one of the major drivers for this market is the rising prevalence of mental illnesses.

Further, the report states that one of the major factors hindering the growth of this market is the side effects of antidepressants.

The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • Allergan Plc
  • Eli LillyCo.
  • GlaxoSmithKline Plc
  • H. Lundbeck AS
  • Pfizer Inc.
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4804046
Adroll
adroll